Catalent expands UK clinical supply facility

Published: 10-Oct-2007
Regulatory Logistics

Catalent Pharma Solutions, a provider of outsourced clinical and commercial packaging services, is expanding its temperature-controlled warehouse in Bolton, UK to meet increased customer demand for clinical supply services, especially cold-chain storage and distribution.


Catalent Pharma Solutions, a provider of outsourced clinical and commercial packaging services, is expanding its temperature-controlled warehouse in Bolton, UK to meet increased customer demand for clinical supply services, especially cold-chain storage and distribution.

The expansion involves a purpose-built extension of the existing facility and is expected to be operational in June 2008. With a floor space of over 7,500 sq ft (700 sq m) and over 2,700 controlled ambient storage locations, the new temperature controlled warehouse will also house a 320-pallet refrigerator.

This development comes soon after two already completed expansions at Catalent's other clinical supply facilities in Europe (Schorndorf, Germany) and the US (Philadelphia, PA). Through these expansions, Catalent has enhanced capability to support global projects requiring cold-chain storage and distribution of clinical materials.

"Customers are increasingly outsourcing clinical development, especially cold-chain distribution," explained Frank Lis, vice-president and general manager of Global Clinical Supplies for Catalent. "By continuing to expand our global clinical supply service facilities, we are able to better serve our expanding customer base throughout the world."

  • Companies:
  • Catalent
See more

You may also like

Distribution

Catalent enters commercial supply agreement

Read more
Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  3. Tagrisso receives full approval in the EU For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Partnering for successful commercial biologic manufacturing

There are a number of challenges and potential pitfalls when manufacturing a biologic drug in preparation for commercial launch and there are four key areas that can impact the success of scale-up: manufacturing; meeting regulatory expectations; demand forecasting; and process validation
Manufacturing

Why outsourcing makes sense for orphan and rare diseases

There are as many as 8000 rare diseases, affecting 400 million people worldwide, for which there are no effective drugs available.<sup>1</sup> With patient numbers being so low for each rare disease, it is often difficult for a pharmaceutical company to achieve a return on its investment on a drug development programme or treatment without additional incentives.
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Manufacturing

Catalent invests $50m at Bloomington facility

The line is expected to be operational by April 2021 and will add capacity to support the growing pipeline of clinical programs and commercial launches at the site
Regulatory

Catalent partners with Humanigen to support FDA-approved Phase III Lenzilumab study for COVID-19

From its Philadelphia facility, Catalent has provided clinical supply support to Humanigen and its partners to accelerate the instigation of this clinical trial
Manufacturing

Catalent client gets FDA approval for generic bronchodilator

Approval has marked the first generic metered-dose inhaler to be approved by the FDA in over twenty years and will now be scaled-up
Subscribe now